The abstract is read at the publisher; the summary is JClub's.
Once-weekly survodutide in adults with obesity without diabetes produced mean body-weight reductions of -12.2% (3.6 mg) and -13.0% (6.0 mg) at week 76 versus -5.4% with placebo.
- Why it matters: GLP-1–based obesity drugs improve outcomes, but additional options are needed for stronger weight loss in people without diabetes.
- What they did: In a phase 3 double-blind trial of 725 adults (BMI ≥30 or ≥27 with an obesity complication), participants received subcutaneous survodutide (up to 3.6 mg or 6.0 mg) or placebo plus lifestyle counseling; primary endpoints were percent weight change and ≥5% loss at week 76.
- The result: At week 76, 72.6% (3.6 mg) and 71.9% (6.0 mg) achieved ≥5% weight reduction versus 46.3% with placebo (P<0.001 for all comparisons); gastrointestinal adverse events were most common (80.9%, 89.7%, 47.9%), with no deaths reported.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 1 cited this week
- Open access